
Cancer Center, Dana-Farber, more receive $1.2M from family foundation
Cincinnati Business Courier highlights pediatric brain tumor research
The Cincinnati Business Courier highlighted a $1.2 million grant received by the University of Cincinnati Cancer Center's Timothy Phoenix and colleagues at Dana-Farber Cancer Institute and the German Cancer Research Center to study pediatric low-grade gliomas.
Low-grade gliomas are one of the most common types of brain tumors and are associated with overall better survival outcomes, but these tumors and associated treatments still have a large impact on quality of life for kids, Phoenix said.
“There’s been progress the past decade, and just last year there were multiple new drugs approved by the FDA that show efficacy and promise,” said Phoenix, PhD, a Cancer Center researcher and associate professor in UC’s James L. Winkle College of Pharmacy. “But we still don’t have a curative therapy for low-grade gliomas.”
Using experience from developing models of pediatric high-grade gliomas, Phoenix and his colleagues will develop new models of pediatric low-grade gliomas to better understand their biology and growth patterns across brain development and maturation.
“There’s really no good model for this disease, so we’ll be using our system to try to understand how these tumor cells interact with the normal brain during development and how that influences the start-and-stop growth pattern that they see in the clinic,” he said. “If we can improve and understand why this occurs and why after a certain age the chance of growth diminishes, then hopefully we can develop therapies that target these interactions.”
Read the Cincinnati Business Courier article.
Featured photo at top of Phoenix working in his lab. Photo/Andrew Higley/UC Marketing + Brand.
Related Stories
Cancer Center, Dana-Farber, more receive $1.2M from family foundation
March 28, 2025

The Cincinnati Business Courier highlighted a $1.2 million grant received by the University of Cincinnati Cancer Center's Timothy Phoenix and colleagues at Dana-Farber Cancer Institute and the German Cancer Research Center to study pediatric low-grade gliomas.
Researcher developing pancreatic cancer treatment that targets newly identified protein
September 30, 2025
MSN highlighted the University of Cincinnati Cancer Center’s Ahmet Kaynak's research that examined the unique tumor microenvironment of pancreatic ductal adenocarcinoma cells, identified one of the key proteins that aids tumor treatment resistance and developed a new drug targeting this protein that reduced tumor size and increased survival in animal models.
Understanding resistance to targeted therapies in head and neck, breast cancer
July 11, 2025

MSN highlighted University of Cincinnati Cancer Center and Cincinnati Veterans Affairs Medical Center research published in the journal Oncotarget that reviewed current research on why Epidermal Growth Factor Receptor-targeted therapies often fail in breast and head and neck cancers.